Find cancer before it finds you
Empowering non-invasive early detection with unparalleled tumor DNA precision
Find cancer before it finds you
The first to detect
cancer before imaging
Using Rarcells’ proprietary ISET® technology, independent researchers detected cancer years before it appears on CT scans – redefining what early detection means.
Unmatched Sensitivity and Precision
CE-IVD-certified and independently audited, ISET® can identify as few as a single tumor cell among millions within just 10 mL of stabilized blood. This level of performance establishes a new global standard for accuracy and reliability in cancer detection.
ISET® CTC-DNA:
Advancing the future in liquid biopsy
Rarecells is tackling the toughest challenges in early and recurrent cancer detection – pushing the limits of non-invasive diagnostics.
By combining analysis of circulating tumor cells DNA (CTC-DNA) analysis with circulating tumor DNA (ctDNA) tests, Rarcecells’ next generation technology dramatically enhances sensitivity, outperforming current liquoid biopsy approaches.
Comprehensive Genomic Insights
Through the simultaneous analysis of CTCs and ctDNA, Rarecells uncovers a richer genomic landscape that mirrors the true complexity of cancer.
This enables more accurate clinical decision-making and personalized treatment strategies across cancer types.
From proven science to market adoption
Rarecells’ breakthrough ISET® technology has been featured in more than 125 independent publications and tested in over 6,000 patients – and is now helping people to detect cancer earlier through commercial cancer testing in Paris.